Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
复制标题
DOI:
10.1007/s11914-017-0380-1
复制
发表时间:
2017-08
影响因子:
4.3
通讯作者:
Boyce AM
中科院分区:
文献类型:
--
作者:
Boyce AM
Denosumab is an inhibitor of receptor activator of nuclear factor kappa-B ligand (RANKL), and has emerged as an important novel therapy for skeletal disorders. This article examines the use of denosumab in children. Considerable safety and efficacy data exists for denosumab treatment of adults with osteoporosis, bone metastases, and giant cell tumors. Pediatric data is limited; however, evidence suggests denosumab may be beneficial in decreasing bone turnover, increasing bone density, and preventing growth of certain skeletal neoplasms in children. Denosumab’s effect on bone turnover is rapidly reversible after drug discontinuation, representing a key difference from bisphosphonates. Rebound increased bone turnover has led to severe hypercalcemia in several pediatric patients. Denosumab is a promising therapy for pediatric skeletal disorders. At present, safety concerns related to rebounding bone turnover and mineral homeostasis impact use of denosumab in children. Research is needed to determine if and how these effects can be mitigated.
登录
查看更多内容
DOI:
10.1159/000381045
发表时间:
2015-01-01
期刊:
CALCIUM AND BONE DISORDERS IN CHILDREN AND ADOLESCENTS, 2ND EDITION
影响因子:
--
作者:
Hogler, Wolfgang;Ward, Leanne
通讯作者:
Ward, Leanne
影响因子:
6.2
作者:
Gerstenfeld, Louis C.;Sacks, Daniel J.;Einhorn, Thomas A.
通讯作者:
Einhorn, Thomas A.
影响因子:
8.4
作者:
Diel, Ingo J.;Body, Jean-Jacques;Braun, Ada
通讯作者:
Braun, Ada
影响因子:
5.8
作者:
Bone, Henry G.;Bolognese, Michael A.;Martin, Javier San
通讯作者:
Martin, Javier San
影响因子:
45.3
作者:
Henry, David H.;Costa, Luis;Yeh, Howard
通讯作者:
Yeh, Howard